• Home
• Investors
• Annual Review 2006
• Chairman's and CEO's closing letter

Chairman's and CEO's closing letter

Dear shareholder

As this Annual Review has demonstrated, we continue to meet the challenges of improving productivity in R&D and ensuring that patients have access to medicines, wherever in the world they live.

For all our investment in technology, it is our people that make GSK so different. We could not succeed without their commitment, expertise and passion, and we thank them all for their outstanding efforts in 2006.

We also thank you, our shareholders, for your continued support during the year, together with our suppliers and business partners who work so hard on our behalf.

Our management team has again performed very well. In the past 12 months we welcomed to the Board Dr Moncef Slaoui, our new Chairman of R&D, on 17 May 2006, Dr Daniel Podolsky on 1 July 2006 and Dr Stephanie Burns on 12 February 2007. In addition to Moncef, the Corporate Executive Team saw two changes. Jennie Younger left in June 2006 and was succeeded by Duncan Learmouth as Senior Vice President, Corporate Communications and Community Partnerships. Ford Calhoun retired in January 2007 and was succeeded by Bill Louv as Chief Information Officer. Our best wishes go to both Jennie and Ford and we thank them for the valuable skills, great contribution and good humour they brought to their roles over the years.

GSK is your company. The aim of this Annual Review is to highlight our performance and key achievements for you and to showcase some of our plans for the future. We hope we have been successful in that regard.

Thank you again for your support.